Deutsche Bank Defends Arrowhead Amid ~16% Decline, Reiterates Buy

Shares of Arrowhead Research ARWR were clobbered Monday as investors were disappointed with details of the company's dosing commencement in the Phase 2a trial of ARC-520. Shares plunged more than 16 percent to close at $17.37. Deutsche Bank analyst Alethia Young had some reassuring comments for Arrowhead investors in a mid-day research note. She attributed the downside in Arrowhead to "weakness in overall biotech sentiment" and suggested the company "remains the leader on timelines." She sees Arrowhead as "about a year ahead" for the company's HBV study. Young set a fair value estimate for Arrowhead shares within $35 to $45 amid the Phase 2a data. The Deutsche Bank analyst reiterated a Buy rating and $45 price target on shares of Arrowhead Research.
Market News and Data brought to you by Benzinga APIs
Comments
Loading...
date
ticker
name
Price Target
Upside/Downside
Recommendation
Firm
Posted In: Analyst ColorNewsReiterationAnalyst Ratings
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!